Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MM-310 |
Synonyms | |
Therapy Description |
MM-310 is a nanoliposomal formulation of docetaxel that targets EphA2-expressing cells via EphA2-directed antibody fragments on the liposomal surface, potentially resulting in decreased tumor growth (Cancer Res July 15 2016 (76) (14 Supplement) 3912). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MM-310 | MM310|MM 310 | MM-310 is a nanoliposomal formulation of docetaxel that targets EphA2-expressing cells via EphA2-directed antibody fragments on the liposomal surface, potentially resulting in decreased tumor growth (Cancer Res July 15 2016 (76) (14 Supplement) 3912). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03076372 | Phase I | MM-310 | A Study Evaluating MM-310 in Patients With Solid Tumors | Unknown status | USA | 0 |